PressJanuary 31, 2025 Optimi Health Completes Largest MDMA Capsule Batch to Date, Expands Stability Program
PressJanuary 31, 2025 HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition
PressJanuary 31, 2025 Optimi Health Announces Closing of Non-Brokered Private Placement and Debt Settlement
PressJanuary 28, 2025 Mindbio Announces Successful Outcome of Mandatory Independent Safety Audit in Phase 2b Clinical Trials
PressJanuary 28, 2025 atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
PressJanuary 24, 2025 Red Light Holland Appoints Keith Li as Chief Financial Officer and Provides Corporate Updates
PressJanuary 24, 2025 Filament Health Announces Shipment Of Botanical Psilocybin To The University of Wisconsin-Madison
PressJanuary 24, 2025 Rua Bioscience Announces Support for Clinical Study That Harnesses the Potential of Psilocybin-Containing Mushrooms to Treat Methamphetamine Addiction
PressJanuary 24, 2025 Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder
PressJanuary 20, 2025 PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
PressJanuary 17, 2025 Mindbio Provides Update on Multiple Phase 2B Clinical Trials and Technological Developments
PressJanuary 17, 2025 Optimi Health Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand
PressJanuary 17, 2025 Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum
PressJanuary 17, 2025 Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
PressJanuary 17, 2025 Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
PressJanuary 17, 2025 Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
PressJanuary 13, 2025 atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
PressJanuary 6, 2025 Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent
PressJanuary 6, 2025 Optimi Health Completes Second MDMA Shipment to Australia and Expands 2025 Production Forecast to Support Over 5,000 Patients Globally
PressJanuary 6, 2025 SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
